Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NAMS Stock 12 Month Forecast
Average Price Target
$43.43
▲(17.22% Upside)
| Highest Price Target$52.00 | Average Price Target$43.43 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
$44
Buy
18.76%
Upside
Reiterated
11/05/25
Needham
$40→$46
Buy
24.16%
Upside
Reiterated
11/05/25
NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating5:24 PM 2025 PRICE TARGET & ESTIMATE CHANGE Company N.V. (NAMS) RATING BUY PRICE TARGET $46.00 from $40.00 PREV CLOSE $36.53 52-WEEK RANGE $14.06 - $41.47 3Q25 Recap; Obi EU 2H26, PREVAIL Results in 2H26/1H27 NAMS reported 3Q25 financials and provided a corp update. The main development over 3Q25 was acceptance of the obicetrapib (obi) MAA that sets up potential EU approval in 2H26. Recall, Meraniri has obi's EU commercial rights, and NAMS is eligible for royalties ranging from low-double digits to mid-20s. Investor focus remains on the PREV AIL CVOT trial and whether it confirms the 1yr MACE reduction reported in the BROADWAY trial. PREV AIL is event-driven, and results are still expected in 2H26/1H27. We expect NAMS to update readout timelines in 1H26.
H.C. Wainwright
$52
Buy
40.35%
Upside
Reiterated
11/05/25
Optimistic Buy Rating for NewAmsterdam Pharma: Strong Financials, Promising R&D, and Strategic Growth InitiativesValuation and Risks. We reiterate our Buy rating and $52 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value NewAmsterdam based on the contribution of its late stage asset, obicetrapib, for LDL-C lowering (100% PoS) and CV risk reduction (75% PoS); in the U.S. 27% and 53% contribution, respectively, and currently split 10% each contribution for ex-U.S., which we believe higher market penetration based on the size of the addressable markets represents a conservative component in our model.
William Blair
―
Buy
―
Reiterated
11/05/25
Citi
$42→$50
Buy
34.95%
Upside
Reiterated
10/20/25
Goldman Sachs
$30
Hold
-19.03%
Downside
Reiterated
10/17/25
Wells Fargo
$45
Buy
21.46%
Upside
Initiated
08/25/25
Piper Sandler
$37
Buy
-0.13%
Downside
Reiterated
08/11/25
Leerink Partners
$45→$44
Buy
18.76%
Upside
Reiterated
08/07/25
Scotiabank
$52
Buy
40.35%
Upside
Reiterated
08/07/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
Cantor Fitzgerald
$42
Buy
13.36%
Upside
Reiterated
07/30/25
Stifel Nicolaus
$44
Buy
18.76%
Upside
Initiated
06/12/25
Jefferies
$45
Buy
21.46%
Upside
Reiterated
06/11/25
Guggenheim
$35→$41
Buy
10.66%
Upside
Reiterated
03/03/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
$44
Buy
18.76%
Upside
Reiterated
11/05/25
Needham
$40→$46
Buy
24.16%
Upside
Reiterated
11/05/25
NewAmsterdam Pharma's Promising Developments and EU Approval Prospects Drive Buy Rating5:24 PM 2025 PRICE TARGET & ESTIMATE CHANGE Company N.V. (NAMS) RATING BUY PRICE TARGET $46.00 from $40.00 PREV CLOSE $36.53 52-WEEK RANGE $14.06 - $41.47 3Q25 Recap; Obi EU 2H26, PREVAIL Results in 2H26/1H27 NAMS reported 3Q25 financials and provided a corp update. The main development over 3Q25 was acceptance of the obicetrapib (obi) MAA that sets up potential EU approval in 2H26. Recall, Meraniri has obi's EU commercial rights, and NAMS is eligible for royalties ranging from low-double digits to mid-20s. Investor focus remains on the PREV AIL CVOT trial and whether it confirms the 1yr MACE reduction reported in the BROADWAY trial. PREV AIL is event-driven, and results are still expected in 2H26/1H27. We expect NAMS to update readout timelines in 1H26.
H.C. Wainwright
$52
Buy
40.35%
Upside
Reiterated
11/05/25
Optimistic Buy Rating for NewAmsterdam Pharma: Strong Financials, Promising R&D, and Strategic Growth InitiativesValuation and Risks. We reiterate our Buy rating and $52 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value NewAmsterdam based on the contribution of its late stage asset, obicetrapib, for LDL-C lowering (100% PoS) and CV risk reduction (75% PoS); in the U.S. 27% and 53% contribution, respectively, and currently split 10% each contribution for ex-U.S., which we believe higher market penetration based on the size of the addressable markets represents a conservative component in our model.
William Blair
―
Buy
―
Reiterated
11/05/25
Citi
$42→$50
Buy
34.95%
Upside
Reiterated
10/20/25
Goldman Sachs
$30
Hold
-19.03%
Downside
Reiterated
10/17/25
Wells Fargo
$45
Buy
21.46%
Upside
Initiated
08/25/25
Piper Sandler
$37
Buy
-0.13%
Downside
Reiterated
08/11/25
Leerink Partners
$45→$44
Buy
18.76%
Upside
Reiterated
08/07/25
Scotiabank
$52
Buy
40.35%
Upside
Reiterated
08/07/25
TD Cowen
―
Buy
―
Reiterated
08/06/25
Cantor Fitzgerald
$42
Buy
13.36%
Upside
Reiterated
07/30/25
Stifel Nicolaus
$44
Buy
18.76%
Upside
Initiated
06/12/25
Jefferies
$45
Buy
21.46%
Upside
Reiterated
06/11/25
Guggenheim
$35→$41
Buy
10.66%
Upside
Reiterated
03/03/25
Best Analysts Covering NewAmsterdam Pharma Company
1 Month
xxx
Success Rate
6/7 ratings generated profit
Average Return
+5.60%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 85.71% of your transactions generating a profit, with an average return of +5.60% per trade.
3 Months
xxx
Success Rate
7/9 ratings generated profit
Average Return
+30.61%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +30.61% per trade.
1 Year
Success Rate
9/9 ratings generated profit
Average Return
+91.29%
reiterated a buy rating 3 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +91.29% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+129.85%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +129.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NAMS Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
21
21
10
6
0
Buy
5
5
3
4
6
Hold
14
12
10
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
38
23
15
10
Each month's total comprises the sum of three months' worth of ratings.
NAMS Financial Forecast
NAMS Stock Forecast FAQ
What is NAMS’s average 12-month price target, according to analysts?
Based on analyst ratings, NewAmsterdam Pharma Company’s 12-month average price target is 43.43.
What is NAMS’s upside potential, based on the analysts’ average price target?
NewAmsterdam Pharma Company has 17.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NAMS a Buy, Sell or Hold?
NewAmsterdam Pharma Company has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is NewAmsterdam Pharma Company’s price target?
The average price target for NewAmsterdam Pharma Company is 43.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $30.00. The average price target represents 17.22% Increase from the current price of $37.05.
The highest analyst price target is $52.00 ,the lowest forecast is $30.00. The average price target represents 17.22% Increase from the current price of $37.05.
What do analysts say about NewAmsterdam Pharma Company?
NewAmsterdam Pharma Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of NAMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.